John Libbey Eurotext

Gériatrie et Psychologie Neuropsychiatrie du Vieillissement

MENU

Which quality of life for the sarcopenic patient? Volume 19, issue 3, Septembre 2021

Authors
1 WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, Division of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgique
2 Service de médecine gériatrique, CHU Lyon, Groupement hospitalier Sud, Pierre-Bénite, France, Inserm U1060, Oullins, France
3 Service de médecine gériatrique, CHU Lyon, Groupement Hospitalier Sud, Pierre-Bénite, France. HESPER EA 7425 Université de Lyon, France
4 Service de gériatrie, Hôpital européen Georges-Pompidou, AP-HP, Paris, France
5 Service de médecine gériatrique, Hôpital Bichat, AP-HP, Paris, France
6 Service de médecine gériatrique, CHU Nice, France
7 Centre de gérontologie clinique Antonin Balmes, CHU Montpellier, France
8 CHU Clermont-Ferrand, France
9 Service de médecine gériatrique, Centre Hospitalier Villefranche-sur-Saône, France
10 Inserm U1125 - Inra/Cnam, Paris, France
11 Gérontopôle, CHU Toulouse, Inserm UMR 1027, France
12 Service de médecine gériatrique, Hôpital Bellier, CHU Nantes, France
13 Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Arabie Saoudite
14 Membres du Groupe Expert Nutrition en Gériatrie (GEGN) sous l’égide de la SFGG
* Correspondance

Sarcopenia is defined as a progressive and generalized loss of muscle strength, muscle mass and physical performance with advancing age. Among the multiple consequences of sarcopenia, the reduction in the quality of life associated with it can undeniably be considered as a major consequence. Quality of life is measured via generic or specific questionnaires. Current research, mainly using so-called “generic” questionnaires, identifies a reduced quality of life in patients with primary age-related sarcopenia, mainly in areas related to functional status and physical performance. A specific quality of life questionnaire could, in combination with a generic questionnaire, provide more precise data on the impact that sarcopenia has on the quality of life of patients. It was in 2015 that the first quality of life questionnaire specific to sarcopenia, the SarQoL®, was developed. Psychometric validation of the SarQoL® has been carried out in several international patient populations indicating excellent internal consistency, reliability and convergent validity and sensitivity to change as well as an absence of floor and ceiling effects. In combination with a generic questionnaire, this specific questionnaire is therefore suitable for measuring the quality of life of populations suffering from sarcopenia, both in research and in clinical practice, both in the context of observational or interventional evaluations.